Anne Julie Verhaeghe
Senior Manager, Life Sciences, KPMG Advisory
- Specialized Master, Pharmaceutical Marketing & Management, ESCP-EAP (Paris, France)
- Pharmacist Degree, University of Ghent (Belgium)
Anne Julie has a wealth of experience in the Life Sciences Industry and as a consultant.
She joined the KPMG Advisory team in Belgium in 2018, to build out the Life Sciences Advisory practice through a variety of service offerings, from strategy to operations.
Prior to joining KPMG, Anne Julie lived and worked for over 15 years in different countries across Europe, US and India. She worked as an independent consultant and has held a variety of leadership and management positions within Commercial Strategy and R&D teams in the Life Sciences Industry, including Pfizer, Novartis and GSK.
Through her experience, she developed extensive managerial, business and technical skills, working with and leading global cross-functional teams and local commercial affiliates. She has expertise at the interface between R&D and commercialization including defining path to market strategies for early clinical stage compounds, portfolio prioritization, launch & life cycle management and business development including commercial due dilligence.
Further, she has had the opportunity to develop business strategies, develop the path to market strategy for a biotech company, accompany the integration of a pharmaceutical service company and she recently has been working on the implementation of a global transformation program for a mid size pharmaceutical company.
Anne Julie is a laureate of the Prince Albert Fund. She obtained a Specialized Master in Pharmaceutical Marketing & Management at the Ecole Supérieur de Commerce de Paris (ESCP) in Paris and a Pharmacist degree at the University of Ghent.
President of the Board of directors of the BBMRI.be
Sofie Bekaert is currently Manager Translational Program at the Flemish Interuniversity Institute for Biotechnology (VIB), where she coordinates the Grand Challenges Program and healthcare-related programs of the regional and national government.
Prof. Sofie Bekaert was trained as a doctor in Applied Biological Engineering. After 10 years of research, setting up a research platform on biological aging, next generation sequencing and biomarkers, she became valorization and innovation manager at Ghent University. In 2010 she initiated the Clinical Research Center at Ghent University Hospital. As the head of Bimetra, she had the responsibility over a dedicated team in the daily management of the central point of contact for facilitation of different aspects of translational biomedical research (ethico-legal aspects, datamanagement and monitoring of clinical trials, research and innovation management within the hospital, biobanking, big data).
Prof. Bekaert is liaising to strategic translational initiatives concerning biobanking and clinical research and innovation, both at the regional and (inter)national level. In 2017 she was appointed president of the Board of directors of the BBMRI.be, the Belgian node within the European biobank infrastructure network, in addition she is councilor within the European, Middle-eastern and African Society for Biorepositories and Biobanking and is involved in multiple societal valorization projects concerning stakeholder involvement and participation in research (e.g. Eupati, King Baudouin Foundation – multistakeholder dialogue for prioritization of research).
Belgian Coordinator BBMRI.be
Annelies Debucquoy graduated in 2004 as Master in Biomedical Sciences. Afterwards, she started a PhD in the Laboratory of Experimental Radiotherapy at the University Hospital of Leuven focusing on the optimization of molecular targeted treatment for rectal cancer patients which led to her PhD degree in 2009. From 2009 until 2016, she continued this research line as a post-doctoral research fellow. During these years, she has built up a considerable research network in the framework of several (inter)national projects that she was involved in. Her main area of research expertise is translational oncology focusing on rectal cancer, radiosenisitizers, biomarkers and functional imaging. Since September 2014, she has been actively involved in different activities of BBMRI.be and BBMRI-ERIC. In April 2016 she started working at the Belgian Cancer Registry as the National Node Director of BBMRI.be.
MSc, Engagement Manager Real World Evidence Solutions
Pierre Chevalier joined IQVIA in July 2009. He holds a master in Business Engineering (Solvay Business School) as well as a master in Philosophy (ULB). Prior to joining IQVIA, Pierre has been working for 4 years as a researcher in the department of Health Economics at the UCL where he was responsible for the development of management tools for hospitals. Next, Pierre was involved for almost 4 years in the quality control as a statistician expert and consultant in postal engineering at the International Post Corporation.
Pierre is a SAS specialist conducting the analysis based on the IQVIA Hospital Disease Database and has developed multiple health economic and budget impact models in various therapeutic areas. His areas of expertise include:
- Longitudinal databases (Hospital Data, UK CPRD, Dutch ClaIQVIA data, LifeLink databases)
- Health Economics modeling (CE models, BIM, oncology forecasting models)
- Statistics (survival analysis, regression models, analyses in SAS, Excel,…).
- Evidence synthesis (NMA)
Johan van Bussel
Dr. Johan van Bussel is head of the healthdata.be department of Sciensano (previously the Belgian Scientific Institute of Public Health, WIV-ISP). In 2009 he obtained his PhD at the Leuven International Doctoral School of Biomedical Sciences as a Doctor in Biomedical Sciences. That same year he joined Sciensano as senior researcher for the European project “European Community Health Indicator Monitoring”.
In 2010 he became head of the Belgian Monitoring Center for Drugs and Drug Addiction, the national focal point of the European Agency and became familiar with the national eHealth platform. In 2014, he started the healthdata.be project, funded by the National Institute for Sickness and Invalidity Insurance (RIZIV). The objectives of this project are the rationalization, standardization and automation of the research data streams in Belgian healthcare.
Johan van Bussel is also national coordinator of the Action point 18 (Patient registers) of the National eHealth plan 2013-2018, and co-coordinator of the national Big Data for Public Health initiative (#dataforbetterhealth). The mission of the healthdata.be platform is the technical and process-based facilitation of the data exchange in the Belgian health sector according to the principle of the one-off multifunctional data collection and the re-use of data to enable the actors in health care to improve public health knowledge and manage health care management, while respecting the privacy of the patient, the healthcare professional and the medical professional secrecy.
Head of National Innovation Office & Scientific-Technical Advice Unit
DG PRE authorisation / National Innovation Office & Sientific-Technical Advice Unit
Federal Agency for Medicines and Health Products
Christophe Lahorte, PhD. is a pharmacist by training and has performed academic research for 6 years at the University of Ghent related to the chemical-pharmaceutical, non-clinical and clinical development of new radiopharmaceuticals for diagnostic and therapeutic use.
Since September 2004 he has been actively involved within the R&D department of the Belgian agency for medicines and health products (FAMHP) in the quality assessment of clinical trial applications (CTA’s) and paediatric investigation plans (PIP’s). Since end 2007 he was member of the Paediatric Committee formulation working group (PDCO FWG) of the European Medicines Agency (EMA) for 3.5 years.
As a quality assessor he was also involved in the assessment of national and European scientific advice requests and assisted in several GMP inspections related to radiopharmaceuticals. Since april 2009 has been the head of the FAMHP’s Sientific-Technical/Regulatory Advice & Knowledge Management Unit. As of May 2017 he is also the head of the national Innovation Office at the FAMHP. The Innovation Office is especially focussed on the acceleration and facilitation of innovative medicines and health care products developed by eg. academic research laboratories (universities, research organisations, start-ups) and SME’s as well as large companies. As the head of the Innovation Office, he is the FAMHP´s representative at the EU-Innovation Network (EU-IN) and at the “Medicines and device borderline and combination products co-ordination working group” coordinated by the Heads of Medicines Agencies (HMA) and the EMA. He is currently also a member of the MDCG’s Borderline & Classification Working Group and the New Emerging Technologies (NET) Working Group.
He has gained considerable experience in the field of scientific and technical/regulatory advice, including aspects specifically related to early phase drug development. He has also participated in national and European research projects and educational projects and collaborated with several International Institutions such as the European Institute for Transuranium Elements (ITU, Karlsruhe, Germany) and the International Atomic Energy Agency (IAEA, Vienna, Austria).
Musch obtained a PhD in Pharmaceutical and Biomedical Sciences at the Free
University of Brussels.
She joined the Pharmaceutical Industry (Research oriented) for 8 years where she was responsible for all the chemical and pharmaceutical analytical activities related to the development of new innovative drugs.
She moved to the Federal Public Health services as a senior quality assessor and assisted in several projects related to EMA/CHMP as well as to Generics.
Since August 2004 she was in charge of the R&D department within the Federal Agency of Medicines and Health Products in Belgium.
From February 2009 she has been designed as Director-general for the DG Pre-authorisation She is involved in different working groups related to unmet medical need, early access and clinical research in a broad sense.
Ingrid Maes is co-founder and Managing Director at Inovigate, based in Basel, Switzerland and Antwerp, Belgium.
Ingrid has 30+ years of experience in the pharmaceutical and life science sector, and 20 years’ experience in international leadership roles (Siemens and PwC). She is a health industries sector strategy expert in R&D, manufacturing, commercial and regulatory and bridges the scientific, medical and technology world with business and finance aspects. Ingrid focuses on providing industry insight and analysis, strategy and new business development. She brings insights into the future of the sector. She has conducted multiple business and corporate strategy projects for all major pharma, diagnostic and medical device companies on growth, innovation, new market, market access, portfolio, R&D, clinical development, externalisation and collaboration strategies, digital health.
She is a member of various think tanks and advised FDA and EMA on adoption of innovative technologies.
Ingrid has a master’s in engineering sciences – Chemistry & Biotechnology, Genetic engineering and medicinal chemistry from the University of Brussels.
Koen Norga studied philosophy and medicine at the University of Leuven (Belgium). He completed a paediatric internship and residency at Children’s Hospital Boston (Boston, MA USA) and subsequently a paediatric hematology/oncology fellowship at Texas Children’s Hospital (Houston, TX USA). He obtained a PhD in Molecular & Human Genetics from Baylor College of Medicine (Houston, TX USA).
He is currently heading the Paediatric Oncology Unit at Antwerp University Hospital and he holds a faculty position in Medicine & Health Sciences at Antwerp University (Belgium)
With a keen interest in paediatric drug development he has been a member of the Paediatric Committee (PDCO) at EMA since 2011 and he is currently its vice-chair. He is also co-opted member of the CHMP and member of SAWP.
Sabine de Beuf
Sabine de Beuf is Head of Corporate Communications, Public Affairs and Patient Advocacy at Bristol-Myers Squibb Benelux (BMS).
After having worked for 14+ years in a global leading company in the life science industry, Sabine joined Bristol-Myers Squibb. There, she designs both communication & public affairs programs to help patients get a good understanding of the right medicine at the right time. At BMS, she supports the overall business objectives, developing corporate programs that help BMS to stay ahead of the competition, position the brand and preserve its permission to operate. Some of her key capabilities in this field include corporate reputation, stakeholder management and media relations, as well as crisis and issues management.
Sabine is also dedicated to leading patient advocacy groups, to help shaping the environment for sustainable cancer care and to giving patients a voice. One of her recent initiatives she is particularly proud of is a cancer support hub where patients and their family and friends – via a physical gathering moment and online platform – can share their experiences with each other and find hope www.switchtohope.be
Next to her regular activities, Sabine is also an active member of different boards in the pharmaceutical industry such as pharma.be and EFPIA where she is also a member of the communication task force.
With over 20 years of international experience in the life science, pharmaceutical, IT and technology industries, Sabine also obtained extensive experience in the field of B2B and B2C marketing, where she successfully supported product launches, via amongst other things trainings of sales teams on new products and future roadmaps, as well as the implementation of new innovative tools to improve business performance.
Sabine studied Psychology at Ghent University and Applied Communications at Artevelde University College in Ghent. She is also a certified Nutrition, Health and Lifestyle Coach.
Sabine’s credo: “Positive things happen when you believe in them and go for it!”
Annabelle Bruyndonckx is president of the BRAS Education Group.
She graduated from the Catholic University of Louvain-La-Neuve in 1997 as a Master of Laws, after which she attended selected courses of postgraduate education for industry pharmacists at the Universities of Louvain-La-Neuve, Liège and Brussels.
Annabelle joined Olivier Mignolet at Simmons & Simmons LLP in February of 2013 after having spent more than 14 years at another international law firm, where she headed the Life Sciences Practices. She also worked as a teaching assistant in criminal law and medical law at the Catholic University of Louvain-La-Neuve from 1997-2003.
She is a member of the Brussels Pharma Law Group and the European Food Law Association. With a legal career spanning 20 years, Annabelle’s practice covers all parts of medicinal products and medical devices’ life cycle.
Annabelle has published numerous articles and spoken at many conferences on a variety of pharmaceutical and healthcare related subjects.
Linde Buntinx acquired her PhD in Biomedical Sciences at the Phase I unit of the University Hospital Leuven, focused on the development of target-engagement biomarkers. During her PhD, she was selected for an internship at Amgen (Thousand Oaks, US) at the Neuroscience Early Development department where she was involved in IND development programs for CNS. Thereafter, she was appointed as coordinator of the pediatric clinical research unit at UZ Leuven, responsible for the set-up and implementation of a new trial center. Linde developed a passion for innovative clinical research in a wide-range of therapeutic areas from CNS to dermatology, is highly trained in GxP and certified as Clinical Project Manager (CPM). Currently, she is working as site manager and study coordinator at the Anima Research Center (www.animaresearch.com), a private research clinic for CNS and first line indications, which she founded together with her father, Dr. Erik Buntinx.
Pieter Vankeerberghen studied Industrial Pharmacy, obtained a Ph.D. in Pharmaceutical sciences and holds a master degree in informatics.
After working 4 years in R&D, first in Clinical data management and later as project manager in human pharmacology, he joined the Belgian authorities in 2000. After coordinating the agency ICT projects and developments and playing a coordinating role in EU H/V esubmissions, he leads the DG pré R&D department.
Head of Radiation Therapy, University Hospital Liège
Philippe Coucke graduated in 1984 with Great Honours from the University of
Ghent at the Faculty of Medicine. In 1988 he got the certification of the
European Board of Radiation-Oncology. He has a long career within radiation in
several countries (Belgium, France, Switzerland and Canada). Since October
2006, he is head of the Department of Radiation Oncology Centre Hospitalier Universitaire
Philippe Coucke is a former president of ABRO-BVRO and active member of many other associations within radiology and oncology.
Apart from having several publications, he is a reviewer and member of the editorial board of the Belgian Journal of Medical Oncology, Onco and Revue Médicale de Liège. Professor Coucke received 4 times the ‘Prix Wallon Qualité’ on Global Quality Management (according to EFQM model) in the Walloon Region (in 2015: Ranked first at level 4 « Excellence”).
He has a wide range of clinical, preclinical and laboratory research activities in Switzerland and Belgium.